Quanta completes £9M financing for home dialysis system

Funding round completed

UK-based Quanta Fluid Solutions Ltd, a developer of home haemodialysis systems, has completed a £9 million first-round funding to advance SelfCare+, its dialysis system based on machine and cartridge design that provides simplicity, reliability, portability and high treatment quality to patients with chronic renal disease. This will enable those suffering from chronic kidney disease to the same standard of dialysis at home as is available in clinics.

Quanta was spun out of the engineering group IMI plc, where the core concept and early prototypes for the SelfCare+ system were developed. The founding team has worked together for more than seven years to develop advanced fluidic technologies for medical and other applications.

The financing was co-led by NBGI Ventures, which specialises in medical technology investments, Seroba Kernel, a European life science venture capital firm, and Wellington Partners, a pan-European venture capital group based in Munich. Also participating in the financing was BrainsToVentures, a network of angel investors predominantly based in German-speaking Europe.

The company also announced today the appointment of Johan de Ruiter as Chairman of the Board of Directors. De Ruiter is a member of  BrainsToVentures and has 30 years of medical device and healthcare experience. He was formerly Executive Vice President Dialysis International of Fresenius AG, a leading manufacturer and service provider in the dialysis market.

John Milad, Investment Manager at NBGI Ventures, said, “Quanta is developing the first system that will deliver gold standard haemodialysis treatment at home in a portable, easy-to-use system. This has the potential to improve patients’ quality of life and to provide better health outcomes, while helping to reduce the overall cost of treatment.”

Martin Johnson, Quanta’s CEO, said, “This investment brings together experienced partners with proven track records to support the Quanta team through an exciting period of corporate development. The investors have shown great faith in our technology and engineering which will bring real benefits – both clinical and in terms of quality of life – to patients with renal disease and their families.”

Johnson added, “ There has been little innovation in this segment for decades and the growing demand for home haemodialysis by patients, clinicians and healthcare payors remains a high unmet need.”

End Stage Renal Disease affects millions of patients worldwide and haemodialysis is a more than £25 billion global market.

Currently, haemodialysis is delivered primarily in specialist clinics and centres, but issues of patient benefit, cost and clinic capacity are driving the growth of home haemodialysis. A number of studies have shown that between 30 and 40 per cent of patients could perform self-dialysis at home, compared with current practice in western countries, where fewer than 5 per cent of haemodialysis patients are treated at home.